Transition your therapeutic candidates seamlessly from early-stage primary cell target validation and high-throughput screening assays directly into advanced, physiologically relevant organ-on-a-chip three-dimensional co-culture models.
Creative Biolabs’ specialized in vitro modeling platforms emulate natural tissue architecture, cell-type ratios, and matrix stiffness. By replacing artificial cell lines with highly physiological primary cells, these services deliver deep mechanistic insights into macrophage polarization and extracellular matrix remodeling. Consequently, research teams gain invaluable target-validation datasets and accelerated compound screening capabilities. This biological setup successfully mitigates preclinical pipeline risks and ensures downstream research is built on translatable, highly reliable cellular behavior, avoiding premature failures in costly later-stage animal models.
Inflammatory monocytes and resident tissue macrophages act as pivotal orchestrators during tissue repair, regeneration, and fibrosis. Current biological consensus establishes that these plastic immune cells are not passive bystanders, but active, context-dependent dynamic biosensors that respond to parenchymal stress and directly dictate fibroblast-myofibroblast transitions. Creative Biolabs’ specialized testing services harness these myeloid breakthroughs, providing drug discovery researchers with highly translatable, human primary cell platforms designed to evaluate phenotypic shifts, track multicellular matrix deposition, and de-risk the next generation of targeted anti-fibrotic discovery pipelines.
Fig.1 Macrophages and fibroblasts interact through multiple molecular pathways. 1
Transition your therapeutic candidates seamlessly from early-stage primary cell target validation and high-throughput screening assays directly into advanced, physiologically relevant organ-on-a-chip three-dimensional co-culture models.
Customize your assay systems by co-designing microenvironmental stiffness, targeted macrophage lineages, and precise cell-type stoichiometry mimicking the natural physiology of heart, liver, kidney, or lung tissue.
Ensure reliable experimental outcomes with guaranteed lineage stability and high functional consistency across all our primary human and murine macrophage and monocyte cell populations in every testing format.
Benefit from strict operational quality controls, optimized cell handling protocols, and standardized laboratory workflows designed to generate highly reproducible, clean, and reliable datasets for your discovery programs.
This screening platform evaluates how molecules modulate macrophage polarization. Utilizing multi-color flow cytometry and high-content imaging, we track transitions from inflammatory or pro-fibrotic profiles toward tissue-regenerative, matrix-resolving phenotypes.
Learn More →This platform quantifies how primary macrophages remodel the extracellular matrix. We evaluate candidate compounds by measuring direct collagen endocytosis, matrix-metalloproteinase activation profiles, and key enzymes regulating stable, structurally rigid collagen cross-linking.
Learn More →We provide customizable 3D organotypic models replicating specific pulmonary, hepatic, renal, and myocardial environments. These platforms utilize physiological cell-type ratios and tuneable hydrogel stiffness to evaluate multicellular remodeling under stress.
Learn More →Creative Biolabs leverages decades of focused expertise in myeloid research to design advanced assay environments, ensuring your pipeline is guided by scientists with profound understanding of macrophage biology.
Our laboratory integrates state-of-the-art robotic automation with high-throughput imaging platforms, enabling rapid phenotypic profiling of complex cellular behaviors without sacrificing resolution or reproducibility.
By replacing simplified, flat cell line models with human primary cells in physiological three-dimensional scaffolds, we capture realistic, biologically relevant multicellular interactions in every discovery assay.
According to Published Data, targeting myeloid reprogramming pathways yields superior predictive efficacy rates in anti-fibrotic drug discovery compared to simplified, conventional fibroblast-only screening systems.
Get a Quote Today to accelerate your discovery initiatives.
What cells do you use in your assay systems?
We prioritize primary cells to maintain physiological relevance. Our models utilize primary human PBMCs, primary human tissue-resident cells, or bone marrow-derived cells from animal models. We avoid immortalized cell lines unless specifically requested by the client, as they do not capture physiological state transitions.
How do you measure the resolution or reversal of fibrosis?
We leverage our proprietary collagen endocytosis assay and real-time collagen gel degradation platforms. This allows us to track whether your compound promotes macrophage-mediated physical clearance of established extracellular matrices, providing a quantitative metric for tissue regression.
Evaluate host pathogen interactions and intracellular survival of microbial or parasitic pathogens within primary macrophages, tracking phenotype transitions, clearance kinetics, and inflammatory cascades to accelerate early-stage antimicrobial drug candidate discovery.
Learn More →Explore how polarized macrophages interact with stem cell niches and tissue progenitors to modulate regeneration and wound healing, utilizing advanced co-culture models to track cellular proliferation, trophic signaling cascades, and extracellular matrix remodeling.
Learn More →Creative Biolabs’ specialized platforms for assessing macrophage function in tissue remodeling establish an advanced benchmark in anti-fibrotic discovery research. By pivoting the discovery focus from terminal effector myofibroblasts to their upstream macrophage orchestrators, we equip investigators with translatable analytical systems.
Our scientific team is available to collaborate on the design of tailored experimental protocols structured around the specific molecular targets of your discovery pipeline, please contact us.
Reference